Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.77 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGDR2 | Q9Y5Y4 | 6/20 | 0.40 |
| ▸ | PPARG | P37231 | 2/20 | 0.38 |
| ▸ | PPARA | Q07869 | 2/20 | 0.38 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.37 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | LMNA | P02545 | 2/20 | 0.37 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | GNRHR | P30968 | 1/20 | 0.36 |
| ▸ | STAT3 | P40763 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL349965 | 0.93 | CYP3A4 (0.80) | CYP3A4L3MBTL1ALDH1A1PTGDR2EPHX2 | |
| SCHEMBL19033463 | 0.92 | CYP3A4 (0.76) | CYP3A4L3MBTL1ALDH1A1PTGDR2PPARG | |
| SCHEMBL14733238 | 0.91 | CYP3A4 (0.75) | CYP3A4L3MBTL1PTGDR2PPARGPPARA | |
| SCHEMBL2361747 | 0.91 | CYP3A4 (0.85) | CYP3A4L3MBTL1ALDH1A1PTGDR2EPHX2 | |
| SCHEMBL14733229 | 0.87 | CYP3A4 (0.85) | CYP3A4L3MBTL1PTGDR2EPHX2SMN1; SMN2 | |
| Am-461 SCHEMBL29567409 | 0.87 | CYP3A4 (1.00) | CYP3A4L3MBTL1ALDH1A1PTGDR2EPHX2 | |
| Am-461 SCHEMBL349848 | 0.87 | CYP3A4 (1.00) | CYP3A4L3MBTL1ALDH1A1PTGDR2EPHX2 | |
| Am-461 SCHEMBL14715970 | 0.86 | CYP3A4 (0.84) | CYP3A4L3MBTL1PTGDR2EPHX2SMN1; SMN2 | |
| Am-461 SCHEMBL14715969 | 0.86 | CYP3A4 (0.98) | CYP3A4L3MBTL1ALDH1A1PTGDR2EPHX2 | |
| Am-461 SCHEMBL14715972 | 0.86 | CYP3A4 (0.98) | CYP3A4L3MBTL1ALDH1A1PTGDR2EPHX2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9688624-B2 | DP2 antagonist and uses thereof | BRICKELL BIOTECH, INC. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PANMIRA PHARMACEUTICALS, LLC (US) | 2013-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130053444-A1 | DP2 ANTAGONIST AND USES THEREOF | PTGER2, PTGDR2, PTGES2 | CYP3A4 2497/4885L3MBTL1 2926/4885ALDH1A1 739/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.